Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Emicizumab (also known as ACE910, trade name Hemlibra) is a ...

Class:IdSummation:9678403
_displayNameEmicizumab (also known as ACE910, trade name Hemlibra) is a ...
_timestamp2025-01-13 18:06:42
created[InstanceEdit:9678421] Shamovsky, Veronica, 2020-03-19
literatureReference[LiteratureReference:9678380] Factor VIIIa-mimetic cofactor activity of a bispecific antibody to factors IX/IXa and X/Xa, emicizumab, depends on its ability to bridge the antigens
[LiteratureReference:9678400] Identification and multidimensional optimization of an asymmetric bispecific IgG antibody mimicking the function of factor VIII cofactor activity
[LiteratureReference:9678398] Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity
modified[InstanceEdit:9678437] Shamovsky, Veronica, 2020-03-20
[InstanceEdit:9935178] Shamovsky, Veronica, 2025-01-13
textEmicizumab (also known as ACE910, trade name Hemlibra) is a bispecific humanized monoclonal antibody that restores the function of missing activated clotting factor VIII (FVIII) by bridging activated FIX and FX to facilitate effective hemostasis in patients with hemophilia A (HEMA) (Sampei Z et al. 2013; Kitazawa T et al. 2017, 2020). Emicizumab recognizes the epidermal growth factor (EGF)-like domain 1 of FIX/FIXa with one arm and the EGF-like domain 2 of FX/FXa with the other arm (Kitazawa T et al. 2017). The FVIIIa-cofactor activity of emicizumab is thought to depend on phosphatidylserine-exposed phospholipid membrane (Kitazawa T et al. 2017).
(summation)[Reaction:9678390] Factor IXa binds emicizumab [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by Emicizumab (also known as ACE910, trade name Hemlibra) is a ... (9678403)
Follow Reactome